Company / Interest Expense
SAB Biotherapeutics, Inc. Interest Expense History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$301.6K
FY2023
5-year range
$294.5K / $469.2K
FY2021-FY2023
Trend
+2.4%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $469,151 to $301,584 over the past 2 years.
Based on SEC 10-K filings.
$301,584 in FY2023.
Improved from $469,151 to $301,584 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, interest expense increased 2.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $301.6K | +2.4% |
| FY2022 | $294.5K | -37.2% |
| FY2021 | $469.2K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026